CRTE7A2-01 TCR-T Cell not checked
Corregene Biotechnology Co., Ltd · CRTE7A2
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Drug 1: Fludarabine + Cyclophosphamide Drug 2: Interleukin-2 Drug 3: CRTE7A2-01 TCR-T Cell”In the company’s words, NCT06358053 on ClinicalTrials.gov
- Main trialPhase 1
- “A single center, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in HLA-A\*02:01+ Subjects HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine RP2D of CRTE7A2-01 TCR-T cell injection.”In the company’s words, NCT06358053 on ClinicalTrials.gov
- Other names
- CRTE7A2
Other drugs for Cervical Cancer
- SocazolimabLee's Pharmaceutical Limited · Phase 3
- 9-valent Human Papillomavirus Recombinant VaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 3
- JSKN033Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase 3
- Bulumtatug fuvedotinMabwell · Phase 3
- SHR-A2102Hengrui · Phase 3
- SYS6002CSPC · Phase 3
Coming up1
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 31 Dec 2027 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | |
| Phase 1Unknown | Mar 2023 | CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026